MedStar Health Joins the Cardiometabolic Center Alliance as a Charter Member

The Cardiometabolic Center Alliance (CMCA), founded by Saint Luke’s Mid America Heart Institute is honored to announce the addition of MedStar Health as a Charter Member of the Alliance.  

As a coalition that seeks to establish Cardiometabolic Centers of Excellence nationwide aimed at transforming the treatment of type 2 diabetes (T2D), and related cardiovascular (CV) and renal comorbidities, the CMCA considers MedStar Health an important member of the Alliance.  

“Cardiometabolic disease is one of the most vexing public health threats which places a substantial burden on those living with its effects and those providing care.  The Cardiometabolic Center Alliance is proud to partner with MedStar Good Samaritan and Union Memorial Hospitals in our mission to deliver optimal evidence-based care to patients with cardiometabolic disease by using the successful implementation strategies developed by the Alliance”, said Mikhail Kosiborod, MD, Executive Director of the Cardiometabolic Center Alliance. “It is through our shared efforts that we can accomplish the goal of improving the outcomes of individuals with cardiometabolic disease regardless of where they live.”

“This is an exciting collaboration with endocrinologists and cardiologists working together to employ state of the art and evidenced-based care for our patients with diabetes and heart disease,” said Dana Frank, MD, FACP, chairman of Medicine for MedStar Good Samaritan Hospital and MedStar Union Memorial Hospital. “Not only will we improve our patients’ lives, but we will be able to study the optimal way to implement this across our system and to other systems as well. The potential for research collaboration with our partners in the Cardiometabolic Alliance represents an opportunity to further refine and improve the care we deliver.”

Alliance members will adopt and implement a novel care model designed and successfully implemented by Saint Luke’s Michael & Marlys Haverty Cardiometabolic Center of Excellence in Kansas City, MO. Based on the initial data, under this model the rates of optimal guideline-directed medical therapy substantially increased over the national average, ensuring that patients with T2D receive care that is aimed at both optimizing diabetes management and providing comprehensive cardiovascular risk reduction with therapies proven to improve outcomes. These results are made possible by a unified team of clinicians from across the disease continuum, who focus on holistic, guideline-directed preventative care. Through their participation, Alliance members are contributing to a national registry that tracks treatment patterns and quality of care. As the Alliance enhances its capabilities, improves processes, and expands research opportunities on a national scale, the ultimate goal is improved patient outcomes.